Category Archives: Treatments

Spotlight – MD Anderson Partners with Pfizer for Cancer Research

Spotlight – MD Anderson Partners with Pfizer for Cancer Research

As the field of immuno-oncology continues to grow, many organizations are launching interesting collaborations to speed discovery and trial periods. Recently, the University of Texas MD Anderson Cancer Center announced a strategic partnership with Pfizer to examine new combinations of immunotherapies with other therapies for blood cancers and solid tumors. This collaboration will involve a… Read More…

Spotlight – Roche Unveils an Important Blood Test

Spotlight – Roche Unveils an Important Blood Test

One of the most pressing issues in immuno-oncology is predicting which treatments will be most effective for which patients. While some individuals respond in dramatic ways to current immunotherapies, others show little, if any, improvement after receiving the treatment. Many companies have tried to identify genes and biomarkers that could help them figure out how… Read More…

FDA OKs Checkpoint Inhibitors for New Cancers – What You Need to Know

FDA OKs Checkpoint Inhibitors for New Cancers – What You Need to Know

Some of the most successful approaches to immuno-oncology have dealt with inhibition of the immune checkpoints expressed on cancer cells. These immune checkpoint inhibitor drugs include Keytruda and Opdivo, two of the most popular immunotherapies on the market. Keytruda has been approved as a treatment for metastatic melanoma and non-small cell lung cancer, as well… Read More…

Spotlight – The Struggle to Find a Cancer Vaccine Continues

Spotlight – The Struggle to Find a Cancer Vaccine Continues

With the exception of the HPV vaccine, which is a preventative rather than a therapeutic vaccine, most attempts at formulating a cancer vaccine have fallen flat. Most of the earliest cancer vaccines focused on bolstering the immune system to protect against cancer growth in the body. Sometimes, these vaccines did invoke a strong immune response,… Read More…

Immune Activation Advances Hold Promise for Immuno-Oncology

Immune Activation Advances Hold Promise for Immuno-Oncology

Immuno-oncology has largely changed the landscape of cancer care, but a number of challenges still exist. From judging efficacy to understanding why some people react to the treatment while others do not, researchers are tackling a number of issues. One young startup in Europe is attempting to address the latter question. At present, only about… Read More…

Scientists Consider Using New Animal Models for Immuno-Oncology Research

Scientists Consider Using New Animal Models for Immuno-Oncology Research

Oncological researchers face a major hurdle in trying to model the complexity of the disease, which has led to genetically engineered rats and, most recently, humanized rat models for use in preclinical studies. Scientists have achieved this unique humanized model using a range of genetic engineering technologies, including transcription activator-like effector nucleases (TALENs) and clustered… Read More…

What You Need to Know about Genetic Engineering and Cancer Immunotherapy

What You Need to Know about Genetic Engineering and Cancer Immunotherapy

The biomedical world was revolutionized by the introduction of clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing technology, which may soon have cancer immunotherapeutic applications. Human trials of the technology are drawing nearer, as an advisory committee at the National Institutes of Health recently approved a proposal that would use CRISPR-Cas9 to bolster cancer immunotherapies… Read More…

Is This New Approach the Future of Cancer Care?

Is This New Approach the Future of Cancer Care?

Immuno-oncology promises to destroy both primary and metastatic tumors using an immune-based response. Even more exciting is the possibility of building tumor-specific immunological memory, which means that the body will actually build immunity toward future tumor cells, thus resulting in a lasting remission. By using the body’s own immune systems, oncologists can avoid much of… Read More…

Setbacks on the Path to CAR T Cell Therapy Approval

Setbacks on the Path to CAR T Cell Therapy Approval

Many scientists, physicians, and patients are looking to immuno-oncology as the future of cancer treatment, especially with cutting-edge immunotherapeutic techniques like chimeric antigen receptor (CAR) T cell therapy, which has been called a “living drug.” This phrase refers to the fact that the therapy is derived from the patient’s own living cells. The treatment begins… Read More…

Amazing New Drug Shows Strong Promise for Multiple Tumor Types

Amazing New Drug Shows Strong Promise for Multiple Tumor Types

Recently, BeiGene presented the preliminary findings of an ongoing dose-escalation Phase I study of BGB-A317, a checkpoint inhibitor. The presentation was made at the 2016 Annual Meeting of the American Society of Clinical Oncology in Chicago. BGB-A317, a monoclonal antibody, is designed to bind to PD-1, a receptor on the surface of cells that downregulates… Read More…